Ophthalmic drug effects on the amyloidogenesis of a transforming growth factor β-induced protein (TGFBIp) peptide fragment

Chia-Yu Chang; Steven S-S Wang; You-Ren Lai; Won-Gun Koh; Josephine W Wu; Yi-Hui Chiang

doi:10.1016/j.exer.2024.109932

Ophthalmic drug effects on the amyloidogenesis of a transforming growth factor β-induced protein (TGFBIp) peptide fragment

Exp Eye Res. 2024 May 16:244:109932. doi: 10.1016/j.exer.2024.109932. Online ahead of print.

Authors

Chia-Yu Chang¹, Steven S-S Wang¹, You-Ren Lai¹, Won-Gun Koh², Josephine W Wu³, Yi-Hui Chiang⁴

Affiliations

¹ Department of Chemical Engineering, National Taiwan University, Taipei, 10617, Taiwan.
² Department of Chemical and Biomolecular Engineering, Yonsei University, South Korea.
³ Department of Optometry, Yuanpei University of Medical Technology, Hsinchu City, 30015, Taiwan; Department of Optometry, Mackay Medical College, New Taipei City, 252, Taiwan. Electronic address: P02431@mmc.edu.tw.
⁴ Department of Ophthalmology, En Chu Kong Hospital, New Taipei City, 237, Taiwan. Electronic address: gracechiang168@gmail.com.

PMID: 38762008
DOI: 10.1016/j.exer.2024.109932

Abstract

Drugs that can treat one disease may either be detrimental or beneficial toward another due to possible cross-interactions. Therefore, care in choosing a suitable drug for patients with multiple diseases is crucial in successful patient management. This study explores several currently available ophthalmic drugs used to treat common ocular diseases to understand how they can affect the amyloidogenesis of a transforming growth factor β-induced protein (TGFBIp) peptide fragment found in abundance in the corneal protein aggregation deposits of lattice corneal dystrophy (LCD) patients. Results from this study provided supporting evidence that some drugs intended to treat other diseases can enhance or inhibit fibrillar aggregation of TGFBIp peptide, which may have potential implication of affecting the disease progression of LCD by either worsening or ameliorating it. Comparisons of the different properties of ophthalmic compounds explored in this study may also provide some guidance for future design of drugs geared toward the treatment of LCD.

Keywords: Amyloidogenesis; Lattice corneal dystrophy (LCD); Ophthalmic drug; Transforming growth factor β-induced protein (TGFBIp).